Spinal Muscular Atrophy: Cell-based drug screens for treatment of axonal defects

脊髓性肌萎缩症：用于治疗轴突缺陷的细胞药物筛选

• 批准号: 8049704
• 负责人: Wilfried Rossoll
• 金额: $ 19.38万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8049704
• 关键词: Actins; Address; Affect; Animal Model; Anterior; Axon; Axonal Transport; Biological Assay; Cause of Death; Cell Culture Techniques; Cell Line; Cells; Cellular Assay; Clinical Trials; Complex; Cytoplasmic Granules; Defect; Development; Disease; Effectiveness; Engineering; Fluorescence; Functional disorder; Funding; Future; Genes; Genetic; Goals; Growth Cones; Horns; Human; Incidence; Infant; Infant Mortality; Lead; Messenger RNA; Microfilaments; Molecular; Motor Neurons; Muscle Weakness; Muscular Atrophy; Mutation; Natural regeneration; Nerve Degeneration; Neurodegenerative Disorders; Neuromuscular Diseases; Neurons; Newborn Infant; Pathway interactions; Patients; Pharmaceutical Preparations; Pluripotent Stem Cells; Preclinical Drug Evaluation; Protein Deficiency; Proteins; RNA Splicing; RNA Transport; Reporter; Role; SMN protein (spinal muscular atrophy); Screening procedure; Series; Spinal Cord; Spinal Muscular Atrophy; Stem cells; Synapses; Testing; Therapeutic; Translating; Translational Research; Translations; United States National Institutes of Health; actin 2; axon growth; base; cell type; cofactor; drug candidate; effective therapy; embryonic stem cell; high throughput screening; human disease; innovation; motor neuron degeneration; mouse model; neuron loss; novel; novel strategies; public health relevance; research study

DESCRIPTION (provided by applicant): Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality. SMA is an autosomal recessive neuromuscular disorder characterized by degeneration of the anterior horn motor neurons in the spinal cord, leading to symmetrical muscle weakness and atrophy. It is caused by mutations or deletions in the gene encoding the survival motor neuron protein (SMN), a ubiquitous protein involved in mRNA splicing. It is still unknown why motor neurons are so specifically vulnerable to low levels of SMN and how SMN deficiency selectively causes motor neuron cell death. Currently there is no cure or treatment available to stop its progression. We and others have shown that low levels of SMN lead to axonal growth defects, impaired 2-actin mRNA transport and reduced 2-actin protein levels in growth cones of motor neurons. These findings represent the first known molecular defect in SMN-deficient neurons and suggest an axon-specific function for SMN. We hypothesizes that SMN may act as an important cofactor for the assembly, transport and/or local translation of 2-actin mRNA granules in axonal growth cones. Defects in axonal mRNA localization and translation of 2-actin may contribute to the axonal dysfunction and neurodegeneration typical of SMA. Previous efforts to develop treatments for SMA did not directly target axonal defects in SMN-deficient motor neurons. In this translational research application for funding to the NIH, we propose to perform cell-based high throughput screens for drugs that correct functional deficits in SMN-deficient motor neurons. Firstly, we will use pluripotent stem cell-derived motor neurons to identify drugs that enhance transport of 2-actin mRNA into axonal growth cones. Secondly, we will screen for drugs that raise 2-actin protein levels in growth cones. Novel drug candidates identified in these screens will be validated for effectiveness through a progressive series of tests in cultured primary motor neurons and SMA mouse models. Given the human toll of this disease and the lack of an effective therapy, it is our goal to translate recent progress in understanding the function of SMN in motor neurons into the development of effective drugs for the treatment of SMA. PUBLIC HEALTH RELEVANCE: We propose to use stem cell-derived motor neurons to screen for drugs for the treatment of axonal defects in spinal muscular atrophy. Molecules that raise 2-actin mRNA and protein levels in axons and growth cones have the potential to be used as drugs for the treatment of spinal muscular atrophy and possibly other neurodegenerative human diseases where axonal transport and synaptic defects are implicated.

描述（由申请人提供）：脊髓性肌萎缩症（SMA）是婴儿死亡的主要遗传原因。SMA是一种常染色体隐性遗传神经肌肉疾病，其特征是脊髓前角运动神经元变性，导致对称性肌无力和萎缩。它是由编码运动神经元生存蛋白（SMN）的基因突变或缺失引起的，SMN是一种参与mRNA剪接的普遍存在的蛋白质。目前还不清楚为什么运动神经元对低水平的SMN如此敏感，以及SMN缺乏如何选择性地导致运动神经元细胞死亡。目前没有治愈或治疗方法可以阻止其进展。我们和其他人已经表明，低水平的SMN导致轴突生长缺陷，受损的2-肌动蛋白mRNA运输和运动神经元生长锥中的2-肌动蛋白蛋白水平降低。这些发现代表了SMN缺陷神经元中的第一个已知分子缺陷，并表明SMN具有轴突特异性功能。我们推测，SMN可能作为一个重要的辅因子的装配，运输和/或本地翻译的2-肌动蛋白mRNA颗粒在轴突生长锥。轴突mRNA定位和2-肌动蛋白翻译的缺陷可能导致SMA典型的轴突功能障碍和神经变性。以前开发SMA治疗方法的努力并没有直接针对SMN缺陷运动神经元中的轴突缺陷。在这项向NIH申请资助的转化研究中，我们建议进行基于细胞的高通量筛选，以寻找纠正SMN缺陷运动神经元功能缺陷的药物。首先，我们将使用多能干细胞衍生的运动神经元，以确定药物，提高运输2-肌动蛋白mRNA到轴突生长锥。其次，我们将筛选提高生长锥中2-肌动蛋白水平的药物。在这些筛选中确定的新型候选药物将通过在培养的原代运动神经元和SMA小鼠模型中进行一系列渐进式测试来验证其有效性。鉴于这种疾病的人类死亡人数和缺乏有效的治疗方法，我们的目标是将最近在了解运动神经元中SMN功能方面的进展转化为治疗SMA的有效药物的开发。 公共卫生相关性：我们建议使用干细胞衍生的运动神经元筛选药物治疗脊髓性肌萎缩症的轴突缺陷。在轴突和生长锥中提高2-肌动蛋白mRNA和蛋白水平的分子有可能用作治疗脊髓性肌萎缩症和可能涉及轴突运输和突触缺陷的其他神经退行性人类疾病的药物。